amikacin has been researched along with ellagic acid in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, M; Aihara, KI; Hori, T; Kaneko, Y; Nakamura, S; Niimi, M; Okada, N; Sugasaki, M; Takishita, M; Yasui, S | 1 |
| Khattab, MI; Khorshid, NE; Saeed, ZM; Salem, AE | 1 |
2 other study(ies) available for amikacin and ellagic acid
| Article | Year |
|---|---|
Artifactual prolongation of the activated partial thromboplastin time by amikacin or gentamicin with ellagic acid, but not silica activated reagent.
Topics: Amikacin; Anti-Bacterial Agents; Ellagic Acid; Gentamicins; Humans; Indicators and Reagents; Partial Thromboplastin Time; Silicon Dioxide | 2022 |
Ellagic acid and cilostazol ameliorate amikacin-induced nephrotoxicity in rats by downregulating oxidative stress, inflammation, and apoptosis.
Topics: Amikacin; Animals; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Cilostazol; Ellagic Acid; Inflammation; Kidney; Lipid Peroxidation; Oxidative Stress; Rats; Renal Insufficiency | 2022 |